We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Hemogenyx Pharmaceuticals Plc | HEMO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.014 | 0.87% | 1.629 | 16:35:20 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.614 | 1.614 | 1.70 | 1.629 | 1.615 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 28/3/2024 15:13 by ashleyjv Tax Year for Private Investors?Hemo's was in December and hopefully the results are due to be next Month (April) |
Posted at 14/3/2024 09:57 by countbasie1 ApothekiWhat a hypocrite. You're on here everyday many times a day. Why do you only have the right to do this?What you shouldn't do is advise distressed investors to buy this under 2p ie 1.95 when you are not qualified to give advice to anyone about anything. |
Posted at 05/3/2024 18:03 by dreamtwister the recent placings will be added to the shares in issue march 6th.but also it is the day of the u k budget so investors can expect a blue day as Mr hunt eradicates the stamp duty sanctioned on the investment markets, also on this day The USA congress re-convenes ! |
Posted at 29/2/2024 14:15 by apotheki Absolutely spot on Paul, time and time again this happens to the unwary investor and it's scandalous how easy it is to get away with it. Some of the financial press are complicit in this - on a regular basis. Perhaps they are plain lazy and don't do any research before they write a glowing article for a company promote - or perhaps they are just interested in any old story and just haven't got a conscience. Perhaps they don't have any financial experience at all and are just as unwary as some PIs. My tactic now is that if there is a sudden concerted effort by a co. to ramp its share price and its balance sheet is low on cash then if I'm holding the share I sell into the price spike - more often than not there's a fund raise coming soon.Fundraises Generally A pattern seems to be emerging, where speculative companies run out of cash, then they pump the share price with upbeat-sounding RNSs. Shortly afterwards they announce a discounted placing into any subsequent share price rise. Private investors speculating on these shares, buying the price rises, seem to be lambs to the slaughter. It doesn't seem right to me that shares are still trading, when the company is secretly offering discounted shares to larger investors in placings. It's often obvious from the share price that news has leaked. We really do need the rules changed (and/or enforced), so that shares are suspended when any company decides to do a fundraise. Also we need quicker, cheaper mechanisms for companies to raise cash. In the meantime, there's a simple way to avoid being clobbered by a discounted placing - don't buy or hold any share where the company doesn't have a cash runway of well over 12 months. Ideally investments should be companies which are profitable and cash generative, hence won't ever need to raise more cash just to keep the lights on. Jam tomorrow/ blue sky shares are a graveyard for optimistic investors, avoiding these things has been the biggest boost for my personal portfolio returns. That said, the odd one multibags, which is what excites people. |
Posted at 27/2/2024 10:32 by dreamtwister FindingsScientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells. The journal Blood published the preclinical findings today. By overcoming challenges, such as drug resistance and treatment relapse common to patients with acute myeloid leukemia (AML), the therapy method could provide a less toxic and more effective approach for older and sicker patients who don't quality for stem cell transplants Sadly the Hemogenyx CDX platform remains in the Petri Dish, The technology that raised countless millions in subscriptions from investors to be replaced by the Cd19flt33 Car-T platform which requires Further First aid from the investors wallets🍒 |
Posted at 21/2/2024 20:25 by dreamtwister posted for the information to new investors !no trials "do not come free "sponsorship per patient Ks of dollars ! |
Posted at 17/2/2024 14:29 by dreamtwister desperate attempt posting outdated articles lolGather around fellow investors Hemogenyx are listed on the main market & have used their allowance to issue more Confectie...will Dr Sandler exercise his awarded share options to raise funds ? Paper roses do not smell Sweet x |
Posted at 17/2/2024 14:10 by apotheki Sounds as though 2024 is going to be one hell of a year....Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform HemoGenyx Pharmaceuticals (LSE:HEMO) CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones. Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolizes a pivotal milestone, offering potential life-changing treatments for patients with limited options. Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections. As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike. Proactive interview:::: |
Posted at 16/2/2024 16:55 by apotheki HemoGenyx Pharmaceuticals / LSE:HEMOHemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform HemoGenyx Pharmaceuticals (LSE:HEMO) CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones. Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolizes a pivotal milestone, offering potential life-changing treatments for patients with limited options. Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections. As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike. Proactive interview:::: |
Posted at 28/11/2023 14:20 by dreamtwister the Company to accelerate the completion of work set out in the plan presented and agreed to by the FDA and to re-submit the Investigational New Drug ("IND") applicationSo their you are in Black & White,Hemogenyx has Not Re-Submitted the Application For the IND ! so investors can rule out the Possibility of going Clinical 2023. on the Grounds of a fresh application the FDA will Review within a 30 day timeframe so the fall of 2024 & not before Hemogenyx may participate or advance towards clinical trials, Investors may take into consideration that Dr sandlers Awarded Share options Will be Executed & Added to the Shares in Issue.on approval of the commencement of clinical trials. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
